Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a highly selective small-molecule multi-target tyrosine kinase inhibitor (TKI) primarily targeting VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (Xie et al., 2018). It exhibits superior anti-angiogenic activity in standardized endothelial migration and tube formation assays compared to sunitinib and sorafenib [DOI]. Anlotinib displays rapid oral absorption, high plasma protein binding (93% in humans), and accumulates preferentially in tumor- and angiogenesis-relevant tissues [DOI]. Preclinical safety studies indicate a high LD₅₀ (1735.9 mg/kg, oral, 14-day, rat), low systemic toxicity, and no significant genotoxicity [DOI]. APExBIO provides rigorously characterized Anlotinib (hydrochloride) (SKU C8688) for reproducible research use [product page].

Biological Rationale

Angiogenesis, the formation of new blood vessels, is essential for tumor growth, invasion, and metastasis (Xie et al., 2018). Vascular endothelial growth factor (VEGF) is the primary regulator of this process, acting through receptor tyrosine kinases, notably VEGFR2, PDGFRβ, and FGFR1. Persistent angiogenesis is a hallmark of malignancy, enabling tumors to surpass a critical size (~1 mm³) [DOI]. Targeting endothelial cell signaling offers advantages over direct tumor cell cytotoxicity, as endothelial cells are genetically more stable and less prone to resistance [DOI]. Therefore, selective inhibition of angiogenic receptor tyrosine kinases is a validated strategy in cancer research.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule TKI that occupies the ATP-binding pocket of VEGFR2, PDGFRβ, and FGFR1, leading to inhibition of their kinase activity [DOI]. This results in blockade of downstream signaling, notably the ERK pathway, which is important for endothelial cell proliferation and migration. Anlotinib inhibits VEGF-, PDGF-BB-, and FGF-2-induced endothelial cell migration and capillary-like tube formation in a concentration-dependent manner. The inhibitory effects are quantified as IC₅₀ values of 5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), and 11.7 ± 4.1 nM (FGFR1), demonstrating high potency [Table 1]. Compared to sunitinib, sorafenib, and nintedanib, anlotinib shows greater selectivity and efficacy in cellular assays [DOI].

Evidence & Benchmarks

• Anlotinib inhibits VEGF-induced HUVEC proliferation with an IC₅₀ in the low nanomolar range (Xie et al., 2018, DOI).
• Capillary tube formation by human endothelial cells is significantly reduced at concentrations ≥ 10 nM (Xie et al., 2018, DOI).
• In rat aortic ring assays, anlotinib blocks microvessel sprouting at 10–100 nM (Xie et al., 2018, DOI).
• Oral bioavailability in rats: 28–58%; in dogs: 41–77% (Xie et al., 2018, DOI).
• High plasma protein binding in humans (93%) and wide tissue distribution, including lung, liver, kidney, heart, and tumor tissue (Xie et al., 2018, DOI).
• High LD₅₀ (1735.9 mg/kg, oral, 14 days, rat), with no significant organ or genetic toxicity (Xie et al., 2018, DOI).
• Superior in vivo tumor growth inhibition compared to sunitinib at equivalent or lower doses (Xie et al., 2018, DOI).

This article extends the discussion in "Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh…" by providing direct benchmarking data and updated pharmacokinetic context for preclinical use. For assay troubleshooting and reproducibility guidance, see "Solving Lab Challenges with Anlotinib (hydrochloride): Sc…", which this article complements by detailing quantitative performance metrics. For workflow optimization in angiogenesis studies, "Anlotinib Hydrochloride: Optimizing Angiogenesis & Cancer…" offers a practical supplement to the present mechanistic and evidence focus.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is applied in cellular assays, such as migration and capillary tube formation with human vascular endothelial cells (e.g., EA.hy 926, HUVECs) to study anti-angiogenic mechanisms. It is a reference standard for VEGFR2/PDGFRβ/FGFR1 inhibition in preclinical cancer biology workflows. The compound is not for diagnostic or therapeutic use in humans or animals. Its effects are distinct from direct cytotoxic agents, as primary action is via inhibition of angiogenic signaling, not induction of tumor cell apoptosis [DOI].

Common Pitfalls or Misconceptions

• Not a direct cytotoxic agent: Anlotinib shows low potency (micromolar range) for direct tumor cell proliferation inhibition in vitro; primary effects are anti-angiogenic [DOI].
• Not suitable for clinical or diagnostic use: For research use only, as stated by APExBIO.
• Requires careful storage: Degraded activity if not stored at -20°C and protected from light/moisture.
• Minimal efficacy in angiogenesis-independent tumors: Activity depends on VEGFR/PDGFR/FGFR-driven angiogenesis.
• Not interchangeable with monoclonal antibodies: Different pharmacokinetics, biodistribution, and specificity profiles [DOI].

Workflow Integration & Parameters

Anlotinib (hydrochloride) is supplied as a powder and should be dissolved in DMSO or aqueous buffer for in vitro assays. Recommended storage is at -20°C. Endothelial cell migration and tube formation assays typically use concentrations of 1–100 nM in serum-free media. For cell-based assays, HUVECs or EA.hy 926 lines are standard. In vivo, oral administration is employed, with bioavailability and pharmacokinetics varying by species (refer to the C8688 kit for details). Product selection and experimental design guidance are further discussed in "Anlotinib Hydrochloride: Elevating Angiogenesis and Tumor…".

Conclusion & Outlook

Anlotinib hydrochloride is a validated, potent, and selective multi-target TKI for anti-angiogenic research. Its robust inhibition of VEGFR2, PDGFRβ, and FGFR1, together with favorable pharmacokinetics and safety profile, position it as a leading tool for preclinical cancer and angiogenesis studies. Ongoing clinical evaluation and mechanistic research will expand its utility and inform next-generation TKI design [DOI]. For reliable and reproducible results, researchers are advised to use rigorously characterized reagents, such as those provided by APExBIO.